SEARCH

SEARCH BY CITATION

References

  • 1
    Summers RW, Switz DM, Sessions JT, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 84769.
  • 2
    Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 24966.
  • 3
    Jones JH, Lennard-Jones JE. Corticosteroids and corticotrophin in the treatment of Crohn's disease. Gut 1966; 7: 1817.
  • 4
    Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salazosulphapyridine in Crohn's disease: a controlled double-blind study. Scand J Gastroenterol 1974; 9: 54954.
  • 5
    O'Donoghue DP, Dawson AM, Powel-Tuck K, Bown RL. Double-blind withdrawal of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2: 9446.
  • 6
    Candy S, Wright JP, Gerber M, Adams G, Gerig M, Goodman R. A double-blind controlled study of azathioprine in the treatment and maintenance of remission in Crohn's disease. Gut 1995; 37: 6748.
  • 7
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 9817.
  • 8
    Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 2159.
  • 9
    Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 4859.
  • 10
    Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999; 94: 324853.
    Direct Link:
  • 11
    Kumar S, Fend F, Quintanilla-Martinez L, et al. Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol 2000; 24: 6673.
  • 12
    Posthuma EFM, Westendorp RGJ, Van Der Sluys Veer A, Kluin-Nelemans JC, Kluin PM, Lamer CBHW. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine. Gut 1995; 36: 3113.
  • 13
    Khatchatourian M, Seaton TL. An unusual complication of immunosuppressive therapy in inflammatory bowel disease. Am J Gastroenterol 1997; 92: 155860.
  • 14
    Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 10815.
  • 15
    Matsueda K, Shoda R, Takazoe M, et al. Therapeutic efficacy of cyclic home elemental enteral alimentation in Crohn's disease: Japanese Cooperative Crohn's Disease Study. J Gastroenterol 1995; 30 (Suppl. 8): 914.
  • 16
    Hirakawa H, Fukuda Y, Tanida N, Hosomi M, Shimoyama T. Home elemental enteral hyperalimentation (HEEH) for maintenance of remission in patients with Crohn's disease. Gastroenterol Jpn 1993; 28: 37984.
  • 17
    Verma S, Kirkwood B, Brown S, Giaffer MH. Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease. Dig Liver Dis 2000; 32: 76974.
  • 18
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359: 15419.
  • 19
    Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 43944.
  • 20
    Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979; 77: 8436.
  • 21
    Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn's disease. Gastroenterology 1979; 77: 898906.
  • 22
    Yao T. Criteria for diagnosis of Crohn's disease (preliminary proposal). In: MutoT, ed. Annual Report of the Research Committee of Inflammatory Bowel Disease. Tokyo: The Ministry of Health and Welfare of Japan, 1996: 636.
  • 23
    Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003; 38: 7406.
  • 24
    Fukuda Y, Kosaka T, Okui M, Hirakawa H, Shimoyama T. Efficacy of nutritional therapy for active Crohn's disease. J Gastroenterol 1995; 30 (Suppl. ): 837.
  • 25
    Zoli G, Care M, Parazza M, et al. A randomized controlled study comparing elemental diet and steroid treatment in Crohn's disease. Aliment Pharmacol Ther 1997; 11: 73540.
  • 26
    Fernández-Banares F, Cabre E, González-Huix F, Gassull MA. Enteral nutrition as primary therapy in Crohn's disease. Gut 1994; 35: S559.
  • 27
    Fernández-Banares F, Cabre E, Esteve-Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. J Parenter Enteral Nutr 1995; 19: 35664.
  • 28
    Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2001; 3: CD000542.
  • 29
    Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995; 108: 105667.
  • 30
    Knight C, El-Matary W, Spray C, Sandhu BK. Long-term outcome of nutritional therapy in paediatric Crohn's disease. Clin Nutr 2005; 24: 7759.
  • 31
    O'Sullivan MA, O'Morain CA. Nutritional therapy in Crohn's disease. Inflamm Bowel Dis 1998; 4: 4553.
  • 32
    Moran A. Bowel rest and elemental diet in Crohn's disease. Gastroenterology 1993; 104: 12389.
  • 33
    Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 18128.